Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.
This announcement is significant as it provides investors and the broader biomedical community with a timely snapshot of Lantern's progress in advancing its pipeline and commercial initiatives. The company is leveraging its proprietary RADR(R) platform and artificial intelligence to transform cancer therapy development. Key pipeline assets include LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
A major development is the commercial launch of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, now available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company and underscores its commitment to commercializing its AI capabilities beyond internal drug development. The platform could accelerate research and reduce costs for partners, potentially reshaping how drug discovery is conducted.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more information, the full press release is available at https://ibn.fm/dVleQ. Investors can access the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.
The upcoming financial results will provide clarity on the company's operational efficiency, cash runway, and the early adoption of withZeta.ai. As a clinical-stage company, Lantern's ability to generate revenue from its AI platform could be a pivotal factor in extending its financial stability and funding its clinical trials. The precision oncology field is highly competitive, and Lantern's AI-driven approach offers a differentiated strategy that may lead to more targeted and effective therapies.
Investors and industry observers will be watching for updates on patient enrollment in the HARMONIC trial, as well as any new data from the LP-184 and LP-284 programs. The company's focus on never-smoker lung cancer patients and pediatric CNS cancers addresses significant unmet medical needs. With the May 15 report, Lantern aims to demonstrate its progress and strategic direction in an era where AI is increasingly integral to drug development.
